// App-Quantinova.ai

: The RIFF Study (Cohort B): A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Lebrikizumab in Combination with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Researchers

Presenter

  • T. M. Maher

Principal Investigators

  • Y. Kondoh

  • T. J. Corte

  • M. K. Glassberg

  • U. Costabel

  • L. H. Lancaster

  • D. Kardatzke

  • J. Kaminski

  • M. Howard

  • J. K. Olsson

  • M. Neighbors

  • R. Owen

  • P. Belloni

Medical Centers

  • University of Miami, Miami, Florida, United States

  • Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany

  • Vanderbilt University, Medical Center, Nashville, United States

  • Genentech Inc., San Francisco, United States

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • PRO Unlimited, Inc., Vancouver, BC, Canada.

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Lebrikizumab

  • Pirfenidone

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved